AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6406458
Drug: amitriptyline, 25
RxNorm normalized name: Perphenazine-Amitriptyline, 25 mg-2 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amitriptyline, 25 mg
Trial: 30666017
Drug: Cold irrigation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold irrigation at 4°C with 17% EDTA and 10 mL of cold saline solution
Trial: 30666017
Drug: Cold irrigation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold irrigation at 2.5°C with 17% EDTA and 10 mL of cold saline solution
Trial: 30666017
Drug: Room temperature
RxNorm normalized name: ROOM DEODORIZER POWDER MENTOR #3202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Room temperature irrigation with 17% EDTA and 10 mL of cold saline solution
Trial: 29364960
Drug: Empiric TB
RxNorm normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empiric TB treatment (n = 82, 49%)
Trial: 29364960
Drug: Median time
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Median time to empiric treatment start
Trial: 12072678
Drug: 0.015 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.015 mg/kg midazolam
Trial: 17599854
Drug: Caffeine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (250 mg in 16 oz of decaffeinated coffee)
Trial: 4062332
Drug: Anthralin minute
RxNorm normalized name: Anthralin
DrugBank: Anthralin (DB11157)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthralin minute entire skin treatment (AMEST)
Trial: 31126331
Drug: sequential-CMAB009 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sequential-CMAB009 therapy
Trial: 27303100
Drug: Topiroxostat 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiroxostat 160 mg daily
Trial: 27303100
Drug: Topiroxostat 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiroxostat 40 mg daily
Trial: 26507720
Drug: Riociguat (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riociguat (1 mg and 2 mg doses, three times daily for 6 days)
Trial: 21138549
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of positive mood color, HAD anxiety, and high TAS score
Trial: 11898780
Drug: Vaccine therapy
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine therapy for melanoma
Trial: 11898780
Drug: Various vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various vaccine strategies
Trial: 11898780
Drug: Cancer immunobiology
RxNorm normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cancer immunobiology underlying vaccine therapy
Trial: 9862635
Drug: Extracellular neurofibrillary
RxNorm normalized name: ACTIVIN RECEPTOR TYPE IIA (SYNTHETIC HUMAN EXTRACELLULAR DOMAIN-CONTAINING FRAGMENT) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (SYNTHETIC HUMAN HEAVY CHAIN FC FRAGMENT), DIMER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extracellular neurofibrillary tangles (eNFTs) stained with antibodies recognizing the 40 carboxy-terminal of Abeta
Trial: 9862635
Drug: Intracellular neurofibrillary
RxNorm normalized name: ACTIVIN RECEPTOR TYPE IIA (SYNTHETIC HUMAN EXTRACELLULAR DOMAIN-CONTAINING FRAGMENT) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (SYNTHETIC HUMAN HEAVY CHAIN FC FRAGMENT), DIMER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracellular neurofibrillary tangles (iNFTs) immunoreactive with antibodies to the 42 carboxy-terminal epitope
Trial: 7545133
Drug: Terfenadine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine (60 mg, twice on the test day)
Trial: 972199
Drug: 0.50 mg
RxNorm normalized name: EVEROLIMUS 0.50 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.50 mg aerosolized terbutaline sulfate
Trial: 21292439
Drug: BTX‐A injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BTX‐A injection
Trial: 31784365
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline injection (Control)
Trial: 27290958
Drug: Nicardipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (20 μg/kg intravenous bolus)
Trial: 27290958
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (comparable volume intravenous bolus)
Trial: 22538219
Drug: Topical SAR
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical SAR 1118 0.1%
Trial: 22538219
Drug: Topical SAR
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical SAR 1118 1.0%
Trial: 22538219
Drug: Topical SAR
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical SAR 1118 5.0%
Trial: 22538219
Drug: Topical SAR
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical SAR 1118 (all doses)
Trial: 17463313
Drug: NeuroThera Laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NeuroThera Laser System (active treatment)
Trial: 15866309
Drug: N-acetylcysteine 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine 600 mg daily
Trial: 14720008
Drug: Budesonide/formoterol (Symbicort)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol (Symbicort) 160/4.5 microg, one inhalation twice daily
Trial: 10554443
Drug: Pain management
RxNorm normalized name: Olu Pain Management 4%-1% Topical Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain management flow sheet implementation; protocols derived from AHCPR guidelines; specific details on dosage and duration not available.
Trial: 9772596
Drug: Fuzheng Huoxue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fuzheng Huoxue Anticancer prescription (FZHXAC)
Trial: 2010627
Drug: Cold-adapted influenza
RxNorm normalized name: INFLUENZA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold-adapted influenza B reassortant vaccine
Trial: 7046990
Drug: Propranolol, 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol, 80 mg four times daily
Trial: 7046990
Drug: Verapamil, 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil, 80 mg four times daily
Trial: 27111333
Drug: Cochlear Implant
RxNorm normalized name: Cochlearia officinalis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cochlear Implant (CI) with standard stimulation pattern (with environmental sound perception)
Trial: 27111333
Drug: Tinnitus Implant
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinnitus Implant (TI) with looped electrical stimulation (without environmental sound perception)
Trial: 21956605
Drug: Dabigatran 150
RxNorm normalized name: dabigatran 150 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran 150 mg once daily
Trial: 21956605
Drug: Dabigatran 75
RxNorm normalized name: dabigatran 75 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran 75 mg once daily
Trial: 21956605
Drug: Dabigatran 75
RxNorm normalized name: dabigatran 75 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran 75 mg twice daily
Trial: 1988829
Drug: Acyclovir (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir (30 mg/kg/day for 10 days)
Trial: 3298070
Drug: Vidarabine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vidarabine (15 mg/kg/day for 10 days)
Trial: 30576866
Drug: Asfotase alfa
RxNorm normalized name: Asfotase alfa
DrugBank: Asfotase alfa (DB09105)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Asfotase alfa 0.3 mg/kg/d subcutaneously (SC) for 6 months
Trial: 30576866
Drug: Asfotase alfa
RxNorm normalized name: Asfotase alfa
DrugBank: Asfotase alfa (DB09105)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Asfotase alfa 0.5 mg/kg/d SC for 6 months
Trial: 30576866
Drug: Asfotase alfa
RxNorm normalized name: Asfotase alfa
DrugBank: Asfotase alfa (DB09105)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Asfotase alfa 0.5 mg/kg/d for 6 months, then 1 mg/kg/d 6 days/week for 4.5 years
Trial: 30130784
Drug: Topical non‐medicated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical non‐medicated preparations including pH‐lowered preparations
Trial: 24559157
Drug: MEDI-546 (0.1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI-546 (0.1, 0.3, 1.0, 3.0, 10.0, or 20.0 mg/kg single dose; 0.3, 1.0, or 5.0 mg/kg/week for 4 weeks)
Trial: 21766974
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg caffeine tablet
Trial: 21766974
Drug: No-pill control
RxNorm normalized name: No Doz Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-pill control condition
Trial: 15167310
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens (CE) 0.625 mg/d
Trial: 15167310
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens (CE) 0.625 mg/d + medroxyprogesterone acetate (MPA) 2.5 mg/d
Trial: 15167310
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens (CE) 0.45 mg/d
Trial: 15167310
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens (CE) 0.45 mg/d + medroxyprogesterone acetate (MPA) 2.5 mg/d
Trial: 15167310
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens (CE) 0.45 mg/d + medroxyprogesterone acetate (MPA) 1.5 mg/d
Trial: 15167310
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens (CE) 0.3 mg/d
Trial: 15167310
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens (CE) 0.3 mg/d + medroxyprogesterone acetate (MPA) 1.5 mg/d
Trial: 9722068
Drug: Glutamine (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine (1.0 g amino acid/m2/dose swish and swallow four times a day)
Trial: 8116534
Drug: High A
RxNorm normalized name: High alcohol lager
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High A (additional vitamin A in intravenous lipids)
Trial: 282081
Drug: active therapy
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: active therapy
Trial: 282081
Drug: no tablets
RxNorm normalized name: caffeine Oral Tablet [No Doz]
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: no tablets
Trial: 30680523
Drug: Aprepitant delayed
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprepitant delayed 1-day administration (125 mg on day 2 and 80 mg on days 3-4)
Trial: 30680523
Drug: Routine triple-antiemetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine triple-antiemetic treatment
Trial: 28357557
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine (0.25 mg/kg diluted to 10 mL with 0.9% saline)
Trial: 28357557
Drug: Placebo (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (10 mL of 0.9% saline)
Trial: 24667487
Drug: levomilnacipran extended-release
RxNorm normalized name: levomilnacipran Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levomilnacipran extended-release (ER)
Trial: 23320901
Drug: S-1 adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 adjuvant therapy (three-week cycle)
Trial: 23320901
Drug: S-1 adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 adjuvant therapy (six-week cycle)
Trial: 21187138
Drug: Individualised herbal
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised herbal prescription
Trial: 16890769
Drug: Grass allergen
RxNorm normalized name: orchardgrass allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grass allergen tablet (GRAZAX, ALK‐Abelló, Hørsholm, Denmark) once daily
Trial: 9389379
Drug: Acadesine (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acadesine (5, 10, 20, 50 mg/kg i.v.)
Trial: 7955799
Drug: MK-383 administered
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-383 administered as 1-hour infusion at 0.25 microgram/kg/min
Trial: 7955799
Drug: MK-383 administered
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-383 administered as 4-hour infusion at 0.15 microgram/kg/min
Trial: 7955799
Drug: Aspirin pretreatment
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin pretreatment (325 mg)
Trial: 3454679
Drug: Memory training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memory training combined with oral physostigmine
Trial: 27837048
Drug: Rituximab early
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab early drug (week 0/1)
Trial: 25421877
Drug: MAP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAP regimen (cisplatin 120 mg/m², doxorubicin 75 mg/m², methotrexate 12 g/m² × 2) pre-operatively followed by MAP or MAP with ifosfamide and etoposide post-operatively for patients with ≥10% viable tumour.
Trial: 25421877
Drug: Pre-operative chemotherapy
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-operative chemotherapy (MAP regimen)
Trial: 21917481
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment (MT group)
Trial: 12351463
Drug: Insulin plus
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin plus troglitazone
Trial: 12351463
Drug: Insulin plus
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin plus metformin vs Insulin plus troglitazone
Trial: 2288138
Drug: Fluid intake
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid intake of less than 500 ml beverages per day
Trial: 2288138
Drug: Fluid intake
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid intake of more than 2500 ml beverages per day
Trial: 31848294
Drug: Higher-dose NaHCO3
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher-dose NaHCO3 (HD-NaHCO3; 0.8 meq/kg of lean body wt per day)
Trial: 31848294
Drug: Lower-dose NaHCO3
RxNorm normalized name: Calendula Flower
DrugBank: Calendula officinalis flower (DB14263)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-dose NaHCO3 (LD-NaHCO3; 0.5 meq/kg of lean body wt per day)
Trial: 23034266
Drug: Oxygen and
RxNorm normalized name: Oxygen and/or oxygen compound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen and Ozone injections
Trial: 23034266
Drug: Pharmacological anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological anti-inflammatory treatment
Trial: 1693038
Drug: Allylestrenol (ALE)
RxNorm normalized name: allylestrenol
DrugBank: Allylestrenol (DB01431)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allylestrenol (ALE) 50 mg daily for 12 weeks
Trial: 1693038
Drug: Chlormadinone acetate
RxNorm normalized name: Chlormadinone acetate
DrugBank: Chlormadinone acetate (DB15903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlormadinone acetate (CMA) 50 mg daily for 12 weeks
Trial: 7193005
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg bromopride
Trial: 31985301
Drug: Halobetasol 0.01%/tazarotene
RxNorm normalized name: HALOBETASOL 0.01%/TAZAROTENE 0.045% LOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halobetasol 0.01%/tazarotene 0.045% lotion (HP/TAZ)
Trial: 31205681
Drug: Mild adverse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild adverse events after manual therapy in men
Trial: 31205681
Drug: Moderate adverse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate adverse events after manual therapy
Trial: 31205681
Drug: No adverse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adverse events after manual therapy
Trial: 28044449
Drug: Curves Complete
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curves Complete 90‐day Challenge (CC, n = 29)
Trial: 19559543
Drug: Injection drug
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection drug use behaviors (including methamphetamine and heroin use)
Trial: 19559543
Drug: History of
RxNorm normalized name: BEMOTRIZINOL 0.8 mL in 100 mL / OCTINOXATE 7 mL in 100 mL TOPICAL CREAM [THE HISTORY OF WHOO GONG JIN HYANG HAE YOON SUN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: History of exchanging sex for money/drugs
Trial: 11867507
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of isoflavones per day
Trial: 10468094
Drug: Vasoactive therapy
RxNorm normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasoactive therapy
Trial: 1352246
Drug: ipsapirone 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ipsapirone 5 mg
Trial: 1352246
Drug: ipsapirone (5-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ipsapirone (5-30 mg per day)
Trial: 6709431
Drug: Isoproterenol aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoproterenol aerosol 0.1% inhalation
Trial: 25703908
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg IM morphine and 60 μg of sublingual desmopressin melt
Trial: 25703908
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg IM morphine
Trial: 23625867
Drug: Individualized heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized heparin and protamine (HMS group, n=29)
Trial: 23625867
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose (ACT group, n=24)
Trial: 18539869
Drug: Acetaminophen alternated
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen alternated with ibuprofen
Trial: 16377643
Drug: Didgeridoo lessons
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Didgeridoo lessons and daily practice at home for four months
Trial: 14645637
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (10 ppm on day 1, followed by 5 ppm for six days)
Trial: 14645637
Drug: Inhaled oxygen
RxNorm normalized name: oxygen Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled oxygen placebo
Trial: 8509566
Drug: Captopril (6.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (6.25 mg initial dose, followed by 12.5 mg 2 hours later and continuing with 12.5 mg three times daily)
Trial: 8509566
Drug: Isosorbide mononitrate
RxNorm normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide mononitrate (initial dose 20 mg followed by 20 mg three times daily)
Trial: 3030173
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplementation (2.7 g eicosapentaenoic acid and 1.8 g docosahexaenoic acid in 15 MAX-EPA capsules)
Trial: 29802852
Drug: Placebo (identical-appearing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical-appearing capsules)
Trial: 24205951
Drug: 5 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g/day of xylitol (5 lozenges of 1 g each, spaced throughout the day)
Trial: 15867235
Drug: Vaccine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine plus radiotherapy
Trial: 10594393
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (10 mg/kg per day in two divided doses for 1 month)
Trial: 8911886
Drug: Immediate release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release fluphenazine (12 mg)
Trial: 8911886
Drug: Slow release
RxNorm normalized name: Slow Release Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow release fluphenazine (12 mg)
Trial: 8911886
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus fluphenazine (2.5 mg)
Trial: 27481855
Drug: Propofol dosing
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol dosing based on total body weight
Trial: 27481855
Drug: Propofol pharmacodynamics
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol pharmacodynamics (PD) measured by the bispectral index